ProCE Banner Activity

CAIRO5: FOLFOXIRI + Bevacizumab vs FOLFOX/FOLFIRI + Bevacizumab in Patients With Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600E-Mutated Primary Tumors

Slideset Download
Conference Coverage
Among patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E-mutated primary tumors, FOLFOXIRI + bevacizumab was associated with superior outcomes vs FOLFOX or FOLFIRI + bevacizumab with an increase in manageable toxicity.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab